The 2026 first-in-human Phase I trial of GZC8072 — a once-weekly oral peptide GLP-1 receptor agonist by Gan & Lee Pharmaceuticals — is designed to answer precisely this question. The 112-participant SAD/MAD study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults and people with overweight or obesity. No efficacy data have been reported; the trial is actively enrolling.
What Is GZC8072 and How Does It Differ From Existing Oral GLP-1 Agents in 2026?
GZC8072 is a biased, ultra-long-acting oral peptide GLP-1 receptor agonist engineered for once-weekly tablet dosing. It differs from oral semaglutide (Rybelsus) in two fundamental respects: it is designed as a biased agonist favouring cAMP signalling over beta-arrestin recruitment, and it is built on Gan & Lee's proprietary NovaPeptide and SupOraTide platforms rather than the SNAC absorption-enhancer approach.
Oral semaglutide achieves approximately 0.8% absolute bioavailability through the SNAC co-formulation strategy, which requires strict fasting and produces high intra-subject pharmacokinetic variability. GZC8072's SupOraTide platform is designed to address these limitations by extending the peptide's effective half-life to support a seven-day dosing interval. The NovaPeptide platform focuses on peptide structural engineering to confer protease resistance and sustained receptor engagement.
Biased agonism at the GLP-1 receptor is a mechanistically significant design choice. Preclinical data published in 2026 in Diabetes, Obesity and Metabolism by Baumer-Harrison and colleagues demonstrated that cAMP-biased GLP-1R agonists maintained glycaemic control with reduced emesis and malaise in mammalian models. These compounds preferentially activate the Gs-protein/cAMP pathway while limiting beta-arrestin-2 recruitment. A parallel 2025 study by Douros and colleagues in Molecular Metabolism confirmed that partial-Gs, cAMP-biased GLP-1R agonists produced more efficacious weight loss in diet-induced obese mice compared with balanced agonists.
GZC8072's biased design is intended to exploit this signalling separation in humans. The compound's intended indications are type 2 diabetes mellitus and weight management in overweight or obesity. Gan & Lee announced receipt of clinical trial approval for both indications from Chinese regulatory authorities, with the first participant dosed on 9 September 2026.
How Is the Phase I Trial Designed — What Are the SAD and MAD Arms?
The Phase I study uses a two-part first-in-human design. The single ascending dose (SAD) arm enrolls healthy adult volunteers and evaluates GZC8072 at escalating dose levels against placebo, with primary endpoints of safety, tolerability, and pharmacokinetic characterisation. The multiple ascending dose (MAD) arm enrolls adults with overweight or obesity and adds pharmacodynamic endpoints including glucose and insulin measures.
In a SAD study, each cohort receives a single dose of the investigational compound or placebo, with safety and pharmacokinetic data reviewed before escalating to the next dose level. This sequential design allows the study team to identify dose-limiting toxicities and establish the maximum tolerated dose before proceeding to repeated dosing. For an oral peptide designed for weekly administration, the SAD arm will characterise the absorption profile, peak plasma concentration (Cmax), time to Cmax, and area under the concentration-time curve (AUC) across the full seven-day post-dose observation window.
The MAD arm is the more clinically informative component for the overweight and obesity population. Participants receive GZC8072 at multiple dose levels over several weeks, allowing assessment of accumulation, steady-state pharmacokinetics, and early pharmacodynamic signals including changes in fasting glucose, postprandial glucose excursions, and insulin secretion. Body weight changes may also be captured as an exploratory endpoint, though the study is not powered for weight-loss efficacy.
A total of 112 participants are planned across both arms, with randomisation to GZC8072 tablets or matching placebo. The study is registered and actively enrolling as of the date of this publication.
Why Is Achieving Predictable Weekly Oral Pharmacokinetics the Central Technical Challenge?
Oral peptide delivery faces three sequential barriers that collectively reduce systemic exposure: gastric acid and pepsin degradation, intestinal protease activity, and low epithelial permeability. Achieving a pharmacokinetic profile stable enough to support once-weekly dosing requires solving all three barriers simultaneously while maintaining sufficiently low inter-subject variability to permit dose selection in Phase II.
The benchmark for comparison is oral semaglutide, which achieves 0.8% absolute bioavailability with a within-subject coefficient of variation exceeding 30% in some pharmacokinetic studies. This variability is clinically consequential: two patients receiving identical doses may achieve substantially different plasma exposures, complicating dose optimisation. A weekly oral formulation faces a more demanding pharmacokinetic target because the drug must maintain therapeutic plasma concentrations across a seven-day interval rather than the 24-hour window of a daily formulation.
Gan & Lee's SupOraTide platform is designed to address the absorption barrier through mechanisms not yet publicly disclosed in peer-reviewed literature. The NovaPeptide platform addresses the half-life extension challenge through structural peptide modifications that resist enzymatic degradation and extend plasma residence time. Published pipeline descriptions indicate that GZC8072 can maintain predictable exposure across seven days, though the pharmacokinetic data supporting this claim will be formally evaluated in the Phase I SAD arm.
What Gastrointestinal Tolerability Profile Is the Trial Designed to Detect?
Gastrointestinal adverse events — nausea, vomiting, diarrhoea, and constipation — are the dominant class-effect of GLP-1 receptor agonists and the primary driver of early discontinuation. The Phase I trial will characterise GZC8072's GI tolerability at each dose level, testing whether its biased agonism design translates to a reduced GI burden versus existing approved agents.
A 2025 network meta-analysis in Nature Obesity by Ismaiel and colleagues quantified GI adverse event rates across approved GLP-1 receptor agonists. Nausea occurred in 20–40% of participants, with rates highest at dose initiation and during escalation phases. Vomiting rates ranged from 8–20%.
Discontinuation due to GI events occurred in 5–10% of participants in pivotal trials of semaglutide and tirzepatide. These figures establish the tolerability benchmark that GZC8072 will be measured against in Phase I. The biased agonism rationale for improved GI tolerability is mechanistically grounded in the role of beta-arrestin-2 recruitment at the GLP-1 receptor.
Beta-arrestin-2 recruitment is associated with receptor internalisation and downstream signalling in the area postrema, the brainstem region mediating nausea and emesis. Compounds that preferentially activate the cAMP pathway while limiting beta-arrestin engagement may therefore produce equivalent metabolic effects with reduced emetic signalling. The Baumer-Harrison 2026 preclinical data support this hypothesis, but human translation remains to be demonstrated.
What Weight-Loss Potential Does the Phase I Design Allow GZC8072 to Demonstrate?
Phase I trials are not powered for weight-loss efficacy; their primary purpose is safety and pharmacokinetic characterisation. The MAD arm's enrolment of participants with overweight or obesity, combined with pharmacodynamic endpoints, will generate early metabolic signals. Any body weight changes observed will be exploratory and hypothesis-generating rather than confirmatory evidence of efficacy.
The weight-loss context matters for interpreting these early signals. Approved injectable GLP-1 receptor agonists achieve 10–22% mean body-weight reduction in pivotal trials at 52–72 weeks. Oral semaglutide 50 mg achieves approximately 15% body-weight reduction at 68 weeks in the OASIS 1 trial, though this requires strict fasting administration and produces higher GI event rates than the injectable formulation.
Gan & Lee's pipeline also includes GZR18, a GLP-1 analogue with once-weekly or bi-weekly injectable dosing. A 2026 study by Ji and colleagues in Diabetes, Obesity and Metabolism reported dose-dependent body-weight reductions ranging from approximately 5% to over 20% for GZR18 across different dose levels and populations. This injectable compound provides an internal benchmark for the GLP-1 receptor engagement achievable with Gan & Lee's peptide engineering platform.
GZC8072 is a structurally distinct oral compound from GZR18, and its weight-loss profile will depend on the oral bioavailability confirmed in Phase I. If the SAD arm validates the predicted pharmacokinetic profile, Phase II dose-finding will be the first study powered to detect meaningful weight-loss signals.
What Is the Regulatory and Development Context for GZC8072 in 2026?
GZC8072 has received clinical trial approval from Chinese regulatory authorities for both type 2 diabetes and obesity indications. It is classified as a Class 1 innovative drug under China's National Medical Products Administration framework. No IND filing or regulatory interaction with the FDA or EMA has been publicly disclosed as of this publication.
The competitive landscape for oral GLP-1 receptor agonists is intensifying. Oral semaglutide (Rybelsus) is approved in the US, EU, and China for type 2 diabetes at doses up to 14 mg daily, with the 50 mg obesity dose under regulatory review in multiple jurisdictions. Pfizer's danuglipron, a small-molecule oral GLP-1 receptor agonist, discontinued Phase III development in 2024 due to liver enzyme elevations, highlighting the safety challenges facing the oral GLP-1 class.
GZC8072's peptide-based design avoids the hepatotoxicity signals associated with small-molecule GLP-1R agonists, though its own safety profile will be characterised in the ongoing Phase I study. The development timeline from Phase I to potential approval in China typically spans six to eight years for a novel compound. The Phase I data will be the first human evidence determining whether that trajectory is viable.
What Safety Considerations Apply to GZC8072 as a Novel Oral Peptide GLP-1 Agonist?
As a GLP-1 receptor agonist, GZC8072 carries class-level safety considerations established across approved agents: gastrointestinal adverse events, hypoglycaemia risk in combination with insulin secretagogues, potential heart rate elevation, and a theoretical pancreatitis signal not confirmed as causal in large cardiovascular outcomes trials. Novel risks specific to GZC8072's oral formulation and biased agonism design will be characterised in Phase I.
The GLP-1 receptor agonist class has an established cardiovascular safety record from large outcomes trials including LEADER (liraglutide), SUSTAIN-6 and SELECT (semaglutide), and SURPASS-CVOT (tirzepatide), all of which demonstrated cardiovascular benefit or neutrality in high-risk populations. GZC8072 will not generate cardiovascular outcomes data in Phase I. These signals require dedicated Phase III cardiovascular outcomes trials enrolling thousands of participants over years.
The oral delivery route introduces formulation-specific safety considerations. Absorption enhancers and structural modifications required to achieve oral bioavailability may have their own tolerability profiles independent of GLP-1 receptor pharmacology. The Phase I SAD arm in healthy volunteers is specifically designed to separate formulation-related tolerability signals from receptor-mediated pharmacodynamic effects.
Practitioners and researchers should note that GZC8072 is an investigational compound with no approved indication in any jurisdiction as of 2026. All data discussed in this article derive from preclinical studies, pipeline disclosures, and the trial design. No Phase I results have been published, and the compound is not available outside the registered clinical trial. Does Oral GLP-1 Receptor Agonism Now Have Clinical Proof Beyond Injectable Peptides — How Do 2026 Oral Obesity Trials Compare with Semaglutide and Tirzepatide on Weight Loss and Tolerability? What Did the First U.S. Phase 2 Mazdutide Trial Show for Weight Loss, HbA1c, and Tolerability in 2026? Does Ecnoglutide's cAMP-Biased GLP-1 Receptor Signaling Translate Into Non-Inferior HbA1c Reduction Versus Dulaglutide With Comparable Tolerability in 2026?